Some Asthma Patients May Be Overmedicated, Doctors Say
Get the world’s most fascinating discoveries delivered straight to your inbox.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered Daily
Daily Newsletter
Sign up for the latest discoveries, groundbreaking research and fascinating breakthroughs that impact you and the wider world direct to your inbox.
Once a week
Life's Little Mysteries
Feed your curiosity with an exclusive mystery every week, solved with science and delivered direct to your inbox before it's seen anywhere else.
Once a week
How It Works
Sign up to our free science & technology newsletter for your weekly fix of fascinating articles, quick quizzes, amazing images, and more
Delivered daily
Space.com Newsletter
Breaking space news, the latest updates on rocket launches, skywatching events and more!
Once a month
Watch This Space
Sign up to our monthly entertainment newsletter to keep up with all our coverage of the latest sci-fi and space movies, tv shows, games and books.
Once a week
Night Sky This Week
Discover this week's must-see night sky events, moon phases, and stunning astrophotos. Sign up for our skywatching newsletter and explore the universe with us!
Join the club
Get full access to premium articles, exclusive features and a growing list of member rewards.
People with mild asthma are advised to lower their medication dose once their asthma has been brought under control, but the best way to reduce the dose is not fully known, doctors say.
As a result, patients may be staying on higher doses than what's necessary to keep their condition under control.
"We need to find a way to help patients control their asthma, without overmedicating them," said Dr. John Mastronarde, director of the Asthma Center at Ohio State University's Wexner Medical Center.
"Right now, the recommendation is to reduce a patient's therapy once the asthma is controlled for at least three months," Mastronarde said. [8 Strange Signs You're Having an Allergic Reaction]
To control asthma, patients typically take drugs called inhaled corticosteroids, to reduce inflammation in the lungs, and long-acting beta agonists (LABAs), to open the airways. Doctors adjust the medication dose based on the patient's symptoms and lung function.
Once a patient's asthma is controlled, the drug dose should be lowered carefully, to the minimum dose necessary, according to the National Institutes of Health's guidelines for treating asthma.
"But that's where things just don't happen," Mastronarde said. "Once you get the symptoms under control, sometimes both the patient and the doctor just leave the patient on whatever they are on, because they don't want it to get worse again."
Get the world’s most fascinating discoveries delivered straight to your inbox.
Although low doses of inhaled corticosteroids are safe, it is thought that taking high doses of the drugs for a long time may weaken the bones, especially in post-menopausal women, or possibly increase the risk of eye cataracts. Higher doses also cost more, Mastronarde noted.
Long-acting beta agonists may have some effects on a person's heartbeat and blood pressure. The U.S. Food and Drug Administration recommends these drugs be used for the shortest time needed to control asthma symptoms, and that they be discontinued if possible.
Although lowering the doses of these medications is recommended, no one knows the best way to do that, Mastronarde said.
To help establish guidelines, Mastronarde and his colleagues are launching a yearlong study to examine 450 people with moderate asthma, who will receive inhaled corticosteroids and beta agonists for eight weeks. For the participants whose asthma is well controlled, the researchers will then see which method would work better: reducing the doses of their medication, or eliminating the beta agonists.
But in the meantime, patients whose asthma is controlled for three months can talk to their doctor about whether they can decrease their medication dose, Mastronarde said.
Email Bahar Gholipour. Follow us @LiveScience, Facebook & Google+. Original article on Live Science.

